Strategic Partnerships Nanoform collaborates with global pharma and biotech partners and has active engagement with Takeda, presenting collaborative proof-of-concept studies. This indicates a receptive environment for expanded co-development and formulation services with large and mid-size pharma players seeking improved solubility and bioavailability strategies.

Clinical Development Recent funding and R&D loan activity alongside facility expansions in Helsinki point to accelerating clinical development programs. This creates opportunities to offer GMP manufacturing scale-up, early-phase formulating services, and process optimization support for nanoformed drug substances.

Geographic Expansion Facility expansions in Helsinki and ongoing Northern Europe focus suggest a capability and readiness to support European clients with local manufacturing and development capacity, reducing supply chain risk and time-to-market for EU-based projects.

Financing Leverage Secured grants and loans for nanoparticle delivery technologies signal strong validation and potential for co-funding partnerships. This environment is favorable for joint funding arrangements, blended financing, or milestone-based collaborations with pharma partners.

Technology Fit Nanoform’s platform technologies address solubility, bioavailability and novel drug delivery needs across small to large molecules using GMP manufacturing and CESS technology. This aligns with opportunities to approach companies facing solubility and formulation challenges in late-stage pipelines.